Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus Olaparib vs NHA in mCRPC (KEYLYNK-010)
NCT03834519Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, open-label trial of pembrolizumab and olaparib in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Merck & Co. Primary endpoints: Overall Survival and Radiographic Progression-Free Survival. Started May 2019; status: completed.
02
Drugs
pembrolizumabolaparib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03834519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03834519.